Navigation Links
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/10/2007

Data Presented on Three S*BIO Compounds at The American Society of

Hematology 2007

SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the data presentation on its most advanced compounds at The American Society of Hematology 49th Annual Meeting and Exposition in Atlanta, Georgia. An oral presentation made on its novel and selective JAK2 inhibitor SB1518 highlighted the therapeutic potential of SB1518 for the treatment of myeloproliferative disorders.

In addition, a poster was presented on S*BIO's orally-active "best-in- class" HDAC inhibitor SB939 detailing its therapeutic potential for the treatment of hematological malignancies while a poster on S*BIO's novel kinase inhibitor SB1317 showed data for the potential treatment of acute leukemias.

"We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders, an area of great unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "We are currently conducting Phase I clinical trials for SB939 in Canada and Singapore, and expect the initiation of Phase I trials in various centers in the U.S. We are also delighted to report data on our Flt3-CDK inhibitor, SB1317. The data presented clearly demonstrate the strength and diversity of S*BIO's pipeline and validate our target-driven approach in developing 'best-in-class' and 'first-in-class' drugs."

Oral Presentation (Session: Molecular Pharmacology -- Novel Therapies I)

SB1518: A potent and orally-active JAK2 Inhibitor for the treatment of myeloproliferative disorders

SB1518, a potent ATP-competitive inhibitor of both JAK2 kinase, and its JAK2V617F mutant, demonstrated therapeutic potential for the treatment of myeloproliferative disorders caused by aberrant JAK2 signaling. JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs).

Poster No. 757

SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies

SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.

Poster No. 747

SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies

SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia

(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Corporate Development

Tel: +65 6827 5000 (Singapore)

Stephen_rhind@sbio.com

Russo Partners:

Tony Russo +1 212-845-4251

Tony.Russo@russopartnersllc.com

Andreas Marathovouniotis +1 212-845-4253

Andreas.Marathis@russopartnersllc.com


'/>"/>
SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
9. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
10. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
11. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , ... April 29, 2016 , ... Coast Dental Fort ... 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck Road ... a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general ...
(Date:4/29/2016)... ... ... Mobility Designed is redefining mobility with their patent pending crutch design. ... distributes body weight from the elbow to the forearm. In consumer tests, users ... other crutches. , Co-founders Max and Liliana Younger were inspired to design the crutches ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Dr. Robert ... dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more patients ... offer allows patients to learn more about the options currently available to them and ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... closing of a growth round of funding led by Eastside Partners, with participation ... the company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... Newport Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Dr. Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are ... the Society for Assisted Reproductive Technology (SART). In April, SART published the ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
Breaking Medicine Technology: